BridgeBio Pharma, Inc. (BBIO)
NASDAQ · Manufacturing · Pharmaceutical preparations
$65.57−$0.7100 (−1.07%) on the dayAs of the close; data may be delayed.
BBIO price, last 12 months
Key stats
- Previous close
- $66.28
- Open
- $66.50
- Day range
- $64.84 – $67.07
- 52-week range
- $48.78 – $93.42
- Volume
- 2.1M
- Avg volume (20 days)
- 2.6M
- Market cap
- $12.8B
Performance
1W−1.6%
1M−17.4%
3M−6.7%
6M−9.7%
YTD−14.3%
1Y+29.5%
vs S&P 500, 1Y+12.7 pts
Technicals and fundamentals
About BridgeBio Pharma, Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $12.8B